View Older Stories View More Recent Stories

Mar 31, 2020 12:03PM Horizon Therapeutics (HZNP) TEPEZZA Significantly Reduces Proptosis Across Patient Subtypes
Mar 31, 2020 12:00PM TEPEZZA™ (teprotumumab-trbw) Significantly Reduces Proptosis (Eye Bulging), a Key Marker of Thyroid Eye Disease, Across Patient Subtypes
Mar 26, 2020 04:15PM Horizon Therapeutics plc Donates $1.5 Million to COVID-19 Response Efforts in Illinois and Other Impacted U.S. and Global Communities
Mar 3, 2020 08:00AM Horizon Therapeutics plc Launches the Down and Out Kidney Campaign to Call Attention to the Prevalence and Impact of Gout in Chronic Kidney Disease
Feb 28, 2020 10:00AM Horizon and Willis Tower Elevate the Need for Rare Disease Innovation on Rare Disease Day
Feb 28, 2020 08:00AM Horizon Therapeutics plc Partners with EveryLife Foundation to Establish $1 Million #RAREis Scholarship for Adults with Rare Diseases
Feb 27, 2020 08:00AM Horizon Therapeutics plc Named One of the Best Workplaces in Ireland
Feb 26, 2020 07:00AM Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2019 Financial Results; Announces Full-Year 2020 Guidance
Feb 18, 2020 08:30AM Horizon Therapeutics plc to Present at the Cowen and Company 40th Annual Health Care Conference
Feb 18, 2020 08:01AM Horizon Therapeutics (HZNP) Announces FDA Approval of New Dosage Form for PROCYSB
Feb 18, 2020 08:00AM Horizon Therapeutics plc Announces U.S. FDA Approval of New Dosage Form for PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Oral Granules
Feb 11, 2020 08:00AM Uplifting Athletes Announces Horizon Therapeutics plc as Exclusive Sponsor to Help Tackle Rare Disease at the National Football League (NFL) Scouting Combine
May 16, 2019 08:00AM Horizon Therapeutics plc Launches New Data-Driven Campaign to Reset the Dialogue on Gout
May 9, 2019 08:00AM Horizon Therapeutics plc Announces Tina Ventura as a Healthcare Businesswomen's Association 2019 Luminary
May 8, 2019 07:04AM Horizon Therapeutics plc Reports Strong First-Quarter 2019 Results; Increases Full‐Year 2019 Net Sales and Adjusted EBITDA Guidance
Apr 26, 2019 02:01PM Horizon Pharma (HZNP) Announces New Data from Phase 3 Teprotumumab Trial Shows Dramatic Reduction in Proptosis
Apr 26, 2019 02:00PM New Data from Phase 3 Teprotumumab Trial (OPTIC) Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Morbidity in Active Thyroid Eye Disease (TED)
Apr 16, 2019 08:00AM Horizon Pharma plc and Gift of Adoption Announce a New Fund to Facilitate Global Adoptions of Children with Rare Diseases
Apr 12, 2019 08:00AM Horizon Pharma plc to Present Results from its Phase 3 Teprotumumab Trial (OPTIC) at the 2019 American Association of Clinical Endocrinologists (AACE) Scientific and Clinical Congress
Apr 11, 2019 04:45PM Horizon Pharma plc Named One of the 2019 Best Workplaces in Health Care and Biopharma by FORTUNE and Great Place to Work®
Apr 9, 2019 04:05PM Horizon Pharma plc to Release First-Quarter 2019 Financial Results and Host Webcast on May 8, 2019
Apr 4, 2019 04:05PM Horizon Pharma plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 18, 2019 08:00AM Horizon Pharma plc Wins PR News CSR Award for Partnership with Perspectives Math and Science Academy
Mar 1, 2019 05:50PM Horizon Pharma plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 28, 2019 07:00AM Horizon Pharma plc Announces Phase 3 Confirmatory Trial Evaluating Teprotumumab (OPTIC) for the Treatment of Active Thyroid Eye Disease (TED) Met Primary and All Secondary Endpoints
Feb 27, 2019 07:00AM Horizon Pharma plc Reports Record Fourth-Quarter and Full-Year 2018 Net Sales Driven by Orphan and Rheumatology Segment; Announces Full-Year 2019 Guidance
Feb 25, 2019 08:00AM Horizon Pharma plc to Participate in Cowen and Company 39th Annual Health Care Conference
Jan 29, 2019 08:00AM Horizon Pharma plc to Release Fourth-Quarter and Full-Year 2018 Financial Results and Host Webcast on Feb. 27, 2019
Jan 3, 2019 08:00AM Horizon Pharma plc and HemoShear Therapeutics Enter into Exclusive Drug Discovery Collaboration in Gout
Dec 27, 2018 08:01AM Horizon Pharma (HZNP) Announces FDA Approval to Expand Age Range for RAVICTI Oral Liquid to Include Newborns
Dec 27, 2018 08:00AM Horizon Pharma plc Announces FDA Approval to Expand the Age Range for RAVICTI® (glycerol phenylbutyrate) Oral Liquid to Include Newborns
Dec 17, 2018 08:00AM Horizon Pharma plc to Present at the 37th Annual J.P. Morgan Healthcare Conference
Nov 16, 2018 08:00AM Horizon Pharma plc to Participate in Upcoming Conferences
Nov 7, 2018 07:00AM Horizon Pharma plc Reports Third-Quarter Net Sales Growth of 20 Percent Driven by Orphan and Rheumatology Net Sales Growth of 25 Percent; Increases Full-Year 2018 Adjusted EBITDA Guidance
Nov 2, 2018 09:30AM The Chicago Tribune Names Horizon Pharma plc a 2018 Top Workplace
Oct 29, 2018 05:57PM Horizon Pharma plc Announces Presentation of Results of 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab at 2018 American Academy of Ophthalmology (AAO) Annual Meeting
Oct 25, 2018 01:00PM Horizon Pharma plc Presents Multiple Retrospective Analyses Showing Kidney Transplant Recipients Have Higher Rates of Gout and Increased Disease Severity
Oct 25, 2018 08:00AM Horizon Pharma plc to Participate in Investor Conferences in November
Oct 22, 2018 08:00AM Horizon Pharma plc Announces Multiple Data Presentations Highlighting the Growing Burden of Uncontrolled Gout at the 2018 ACR/ARHP Annual Meeting
Oct 18, 2018 09:16AM FORTUNE and Great Place to Work® Name Horizon Pharma plc to 2018 Best Small & Medium Workplaces for Third Consecutive Year
Oct 10, 2018 08:00AM Horizon Pharma plc to Release Third-Quarter 2018 Financial Results and Host Webcast on Nov. 7, 2018
Oct 4, 2018 09:05AM HighPoint Resources (HPR) Announces Presentation of Data From 48 Week Off-Therapy Follow-Up to Phase 2 Trial of Teprotumumab
Oct 4, 2018 09:02AM Horizon Pharma plc Announces Presentation of Data From 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab
Sep 27, 2018 11:00AM The North American Pediatric Renal Trials and Collaborative Studies and Horizon Pharma plc Announce New Long-Term Cystinosis Registry
Sep 27, 2018 08:05AM Horizon Pharma plc (HZNP) Initiates Clinical to Evaluate KRYSTEXXA with Methotrexate to Enhance Response Rates for People Living with Uncontrolled Gout
Sep 27, 2018 08:00AM Horizon Pharma plc Initiates Clinical Trial to Evaluate KRYSTEXXA® (pegloticase injection) with Methotrexate to Enhance Response Rates for People Living with Uncontrolled Gout
Sep 25, 2018 08:00AM Horizon Pharma plc to Present 48-Week Follow-Up Analysis of the Teprotumumab Phase 2 Trial at the Annual Meeting of the American Thyroid Association
Sep 4, 2018 08:00AM Horizon Pharma plc to Participate in the Morgan Stanley 16th Annual Global Healthcare Conference
Sep 4, 2018 07:00AM Horizon Pharma plc Completes Enrollment of Confirmatory Phase 3 Trial of Teprotumumab Ahead of Schedule
Aug 8, 2018 07:00AM Horizon Pharma plc Reports Record Quarterly Net Sales for Orphan and Rheumatology Segment; Increases Full-Year 2018 Adjusted EBITDA Guidance; Implements New Company Operating Structure to Enhance Focu
View More Recent Stories View Older Stories